Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod
Status:
RECRUITING
Trial end date:
2029-08-01
Target enrollment:
Participant gender:
Summary
A multi-center pilot study to evaluate safety and efficacy of ozanimod as de-escalation therapy in clinically stable MS patients previously treated with anti-CD20 therapy.